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Introduction
Article focus – The issues discussed in this article emerged from 
a 2-year qualitative study that was approved by The University of 
Montana Institutional Review Board (IRB) and funded by the National 
Science Foundation. In phase 1 of this 2-year study, the investigators 
conducted interviews with IRB members from across the country in 
order to examine the norms and processes that IRBs use when assessing 
and monitoring the adequacy of the informed consent process [1,2] . In 
phase 2, the investigators conducted interviews with research subjects 
in order to explore their experiences with the informed consent process 
and their subsequent decisions about participating in human subject 
research. This article, focused on the findings of phase 2, explored 
the following three research questions: (1) How do participants make 
decisions when invited to participate, including their experiences of 
the consent process; (2) what factors influence a decision to enroll in a 
study; and (3) what information do participants want when invited to 
enroll in studies? This study contributes to a growing understanding 
of the decisionmaking processes used by persons who are invited to 
participate in research and factors that need attention when developing 
regulations that will optimize protection of human subjects.
Background 
The US federal regulatory system developed to enhance the ability 
of prospective participants to provide their informed and voluntary 
consent before participating in research evolved from the work of 
the National Commission for the Protection of Human Subjects [3]. 
This commission was convened in 1973 in response to the growing 
challenges posed by the ethics of experimentation; regulatory guidance 
for protecting human subjects became codified in the Common Rule 
in 1991[4]. The Health Insurance Portability and Accountability 
Act (HIPAA) of 1996 added another layer of protection-related 
responsibilities [5].
The US federal guidelines stipulate that the consent process for 
human subjects research has to provide full disclosure of risks and 
benefits, be understandable, take into consideration participant capacity 
and competence, and ensure that consent is voluntary [6,7]. Persons 
must be given information in lay language so that they understand and 
appreciate the research process and associated risks; consent must be 
voluntary and those giving their consent must be legally competent 
to do so [8]. Those standards, although seemingly reasonable, have 
in practice proven difficult to operationalize. By 1999, Sugarman et 
al. had identified more than 377 articles and 3,173 hypotheses when 
conducting a literature review that focused on empirical research 
studying informed consent and how best to achieve it [9]. 
In recent years scholars have focused on topics such as participant 
comprehension and understanding of the research [10-12], how to 
achieve voluntariness [13,14], and policy issues [15,16]. Studies have 
shown that participants seem to be particularly vulnerable when 
trying to understand the key research concepts of clinical trials. Often 
they labor under a therapeutic misconception that leads them to 
believe that participating in a medical study would provide access to 
better treatments or diagnoses [17,18]. Huntington et al. [19] claim 
that although a great deal of thought goes into writing a consent 
document, a very small number of potential research subjects read, 
or understand it, in any detailed way. Moreover, few subjects seem 
to use the informed consent document as a basis for decisions about 
participation. Huntington also found that both the readability and the 
length of the consent form can impede true consent [19]. Other scholars 
assert that research subjects often have an inaccurate or incomplete 
understanding of research and tend to overestimate the benefits of 
participation. In part this occurs because terms such as risk, harm, and 
randomization – terms commonly used in all consent documents – 
may not be well understood by those unfamiliar with research [20]. 
Boiler plate language required to fulfill an institution’s legal obligations 
may seem confusing and irrelevant to the prospective participant.
To overcome many of the deficits that participants bring to the 
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consent process, investigators have focused on approaches for making 
the informed consent process more accessible and understandable. 
Researchers have been encouraged to use consent forms that reflect 
5th or 8th or 10th grade reading levels. Appelbaum and Grisso 
developed a semi-structured interview instrument to assess the 
research participants’ competence in making informed decisions 
about participating in clinical research; their instrument is designed 
to assess skills such as understanding the research and appreciating 
the consequences of participating [21]. While the literature base 
continues to expand, the identification of approaches that optimize 
full disclosure and understanding of the research process remains 
elusive. Indeed some scholars have suggested that the unfortunate 
consequence of the top-down regulatory approach and the focus on 
participant inadequacy seem to have resulted in a system that focuses 
on the obligation to document compliance, rather than the obligation 
to truly achieve informed consent from prospective subjects [22,23].
New challenges to the informed consent process may be emerging 
as clinical research migrates into new environments that engage cadres 
of new researchers as well as an expanded population of potential 
research participants. In years past, clinical research was primarily 
conducted in medical centers or academic medical settings in urban 
communities. While some clinical research still occurs in such settings, 
it is increasingly conducted in community hospitals, clinics, and private 
practice settings, including rural offices where such research engages 
rural clinicians and their patients. This migration has increased to the 
point where the vast majority of industry-funded clinical research now 
occurs in non-academic settings [24-27]. 
The challenges of conveying complex information in an evolving 
research environment underscore the need to better understand how 
participants make decisions when invited to join studies, what factors 
influence such decisions, and what information the participants want 
and need when trying to make informed decisions. Such insights may 
bring us closer to understanding what might be needed to better align 
the federal guidance with research participants’ needs and expectations. 
Research Methods
Sample – Given the exploratory nature of the study a qualitative 
research approach was used [28-30]. In order to develop the sample of 
subjects who had participated in biomedical or non-biomedical human 
subjects’ research, a brief description of the study and invitations to 
participate were sent to selected hospitals, centers, institutes, and 
research settings across the US. These research sites were selected to 
be representative of facilities that serve rural populations. Staff at the 
selected sites then disseminated the information about the study to 
potential participants who were asked to contact the investigators by 
phone or email if willing to participate in interviews. This strategy was 
augmented by a snowball approach [31] whereby research participants 
contacted others who had been invited to participate in research and 
had insights to share. Those willing to participate were then scheduled 
for interviews. After conducting 50 interviews no new information was 
emerging and so saturation was achieved and the interview process 
stopped. This decision is consistent with the standards of qualitative 
research methodology [32,33].
The 50 subjects included those who had participated in clinical 
trials and other types of research (90%) as well as those who had either 
declined or withdrawn (10%) from human subject research. This 
resulted in a sample of 33 females (66%) and 17 males (34%) from states 
across the US. The sample was comprised of 39 participants (78%) over 
the age of 50 and 11 participants (22%) below 50. The higher age of 
the participants was probably due to the fact that people who are ill 
or who have health problems are the ones invited to join or seek out 
participation in clinical trials. These categories of people generally fall 
in older age cohorts.
The education levels among the participants varied, but were 
generally high, with 52% reporting graduate or some graduate 
training, 35% some college experience and the remaining 13% a high 
school education. The kinds of studies described by the participants 
included clinical studies such drugs or devices (72%), psychological, 
sociological, longitudinal, or behavioral (46%), and genetic studies 
(8%). These numbers exceed 100% because some of the participants 
had participated in more than one study and some studies fit more than 
one criterion such as a drug study that includes a genetic component. 
Data Collection – The interviews were conducted exclusively 
by the authors, took place either in person or via telephone, and 
lasted from 45 minutes to one hour. The participant interviews were 
conducted between July 2009 and July 2010. The design of the semi 
structured instrument drew on findings from a pilot study that the 
investigators conducted in 2007 with rural research participants as 
well as the earlier phase of the investigators’ research that focused 
on the decision-making processes used by IRBs when overseeing 
research that involves human subjects [34,35]. Using semi-structured 
interview protocols allows the exploration of unanticipated issues and 
the pursuit of rich examples while adhering to a core set of domains. 
The core domains used in the second phase of the project are listed 
in Table 1. Consistent with established qualitative research practices, 
the interviews continued until data saturation had been achieved, i.e., 
no new data surfaced. The authors transcribed the interviews verbatim 
in preparation for qualitative analysis for which Atlas.ti, a qualitative 
coding software application, was used. The thematic coding was 
conducted by both authors; it evolved as new themes emerged.
Results
A sizeable number of representative quotes are provided to 
showcase the findings of how participants experienced the informed 
consent process and made decisions about enrollment. The quotes 
attest to a remarkable homogeneity, among participants, with respect 
to core beliefs and expectations that influenced or bolstered their 
decisions. 
The consent process – When recounting their experiences with the 
consent process the participants generally seemed to view the process 
as a standard or routine activity and did not seem to question either 
the information or the process itself. Most of the participants (84%) 
reported that they had read the informed consent document and that 
Experiences with research including invitations to participate
Experience with informed consent forms and procedures 
Relationship with the researchers suggesting enrollment 
Factors that influence decision to join: illness, compensation, altruism, personal 
benefits
Role of funding source, purpose of study, and researcher compensation on 
decisionmaking
Perception of voluntarism (ability to decline or withdraw, ‘gentle coercion’?)
Perception of anonymity and confidentiality
Impact of participant vulnerabilities 
Impact of perceived risks and benefits
Future willingness to join a research study 
Information subjects want and need to make informed decisions 
Table 1: Core Domains for Key Informant Interviews.
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they had been given enough time to think about participation before 
making a decision. Many reported that they had had to initial every 
page of the consent form and that the person overseeing the consent 
process underscored the importance of reading and understanding 
the nature of the research study. Some were given the form in advance 
and most reported that they had been encouraged to ask questions. 
Only 3 participants reported that they had felt very rushed during the 
consent process and felt that they did not get enough time to process 
the information.
But in spite of these efforts to fully inform, the data show that 
achieving full understanding of the information provided through the 
consent process can present a number of serious challenges for research 
participants. These challenges seem apparent even for participants 
who, as in this study, are very well educated. As participants appeared 
to make the decision to join a study before the full consent process 
was finalized, reading and signing the consent form became a social 
formality. Consequently, little attention was given to statements about 
risks and benefits, who was funding the research, or protection of 
anonymity and confidentiality. For example, 78% could not remember 
who funded the research study. Most participants thought that the 
research provided valuable benefits such as access to state-of-the art 
medical tests, or the option of getting the best drug. As one respondent 
explained: “Well more for less. Better care and a better cure. My 
treatment would be more complete and there would be less chance of 
reoccurrence.” (p47) 
Factors influencing decisions to participate – The data show 
that the participants’ decisions were influenced by a number of 
factors including illness status (66%), altruism (42%), and financial 
benefit (22%). The potential for personal benefit seemed to play an 
important role when deciding to enroll in a study. This seemed true 
particularly when there was a definite benefit like obtaining a drug or 
device, or some level of monetary compensation. Two thirds of the 
participants acknowledged that they had received some compensation 
for participating. When asked about such compensation, twenty-eight 
percent cited the provision of additional medical tests or medications. 
This is exemplified by the respondent who said: “But I got the drug 
- I am sure the drugs are expensive. The one pill was $150 each and 
I took that twice a day.” (p.40) Twenty-eight percent cited monetary 
compensation as a factor in their decision-making. Explained one 
participant: “When I found out I would get paid, I made up my mind I 
was going to do it.” (p.2) Most of the monetary compensation was quite 
modest and involved benefits such as reimbursements for parking, 
travel, or time and effort. Noted one participant: “Sure. You got $50 
up front and $25 when they drew blood. That was it. That was their get 
rich scheme.” (p17)
The decisions to participate were also influenced by the mode of 
recruitment. Forty-six percent of the participants reported that their 
physician or healthcare provider had suggested they participate, 36% 
that they had responded to a newspaper advertisement or a poster, 
while 28% said the recommendations had come from friends and 
family. Three participants (6%) responded that their participation 
was mandatory in order to get credit for required course work. Since 
some participants offered more than one mode of recruitment for their 
participation in the studies, the numbers do not add up to 100%. 
A trusting relationship with a healthcare provider or researcher 
seems to influence the decisions a prospective human subject makes. 
Participants generally believed that such a person would have the 
subject’s best interest at heart. Said one participant whose physician 
had suggested participation: “[It was my] doctor who recruited me. I 
trust him completely and I love the man.” (p.14) others said it was hard 
to say no if a trusted clinician or a colleague would ask for participation. 
The need to maintain, not disappoint, or not jeopardize a relationship 
was strong among the participants. If a participant had responded to 
an ad about participating, it seemed as if the decision to participate 
was formed more or less at the time of finding out about the study. 
Combining intention with opportunity, one participant explained: “I 
had seen other ads for other research things. I was just curious and we 
were planning to get a flu shot that week. We were going on the cruise 
and wanted the protection.” (p18)
The ability to withdraw from a study, an important component 
of achieving true voluntariness, seemed at times to pose difficulties. 
While most said it would have been easy to withdraw (76%), many also 
said that in practice it would feel like “letting the researchers down” or 
“like ruining the study” (24%). When asked if it would have been easy 
to withdraw from a study, a representative quote was as follows: “Oh 
yeah, at any time. But, I would have felt guilty because I know, as a 
coordinator you put in a lot of work into the study and into recruiting 
people and they pull - and then you can’t use any of the information.” 
(p12). Explained another: “It would have been easy in terms of the 
researcher. I would personally feel like a failure and that it would come 
back to me as karma.”(p35)
Appreciation of risks and benefits – Many participants seemed to 
minimize potential risks and overestimate the benefits of participation. 
Indeed, eighty-eight percent believed that the benefits of participation 
outweighed the risks. They believed that participation would bring 
tangible benefits to oneself or to others and that the risks would be 
minimal or non-existent. This approach to risk assessment, even in 
cases where potentially severe risks were clearly stated in the consent 
documents, is exemplified by the following representative statement: 
“Because I don’t presume there are any risks. They didn’t really talk 
about them. I think that maybe because the form of the medication is 
a nasal spray it is less intense than pills or injections. Maybe there are 
fewer risks? I might have been more leery about medication in pill form. 
Maybe that is naiveté on my part. I guess there is no reason to suspect 
a nasal spray is less potent.” (p38) This statement was made by a well-
educated person whose consent document clearly stated that the risks 
were potentially life threatening. Some participants ignored or refused 
to even read about potential risks or side effects. This approach is seen 
in the following comments: “But I didn’t read about the side effects in 
the informed consent form because I don’t want to slant my thinking.” 
(p14) Another participant explained: “I thought it was a formality - like 
what you sign before surgery, the form saying you might die. It was just 
like the legal language thing and I didn’t take it seriously.” (p4). 
Some participants expressed almost blind trust in the system and 
believed that if a study is allowed to be conducted and is approved, it 
must mean that participating is safe and that the risks are minimal. 
In this context the signing of the consent document was seen more 
as a formality. Participants offered explanations such as: “I didn’t see 
any risks. I do blood draws regularly and that wasn’t scary for me.” 
(p32). Said another: “ I knew it [the drug] had come a long way to get 
to the point where they are doing trials. So I felt comfortable knowing 
there were no real risks, that it was safe.(p12) Another participant 
suggested: “I would not be part of a study where someone from out 
of town comes in to the [local hotel] and recruits local subjects and is 
around for three weeks. It adds legitimacy that it is run locally.” (p18) 
Explained another: “I admit to being fairly trusting - a philosophy in 
my life. Perhaps not always good but I do what is in front of me. It 
was presented in a professional manner in an office setting by a person 
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who was articulate.” (p19) Said another “Well the only thing I thought 
was - well they do stents all the time. I can’t imagine a stent that would 
go wrong and maybe the old ones don’t work well.”(p10). Even a risk 
statement that identified the potential risk for a heart attack would not 
deter a participant who trusted the doctor who suggested participation: 
“Yes. That heart failure was the main risk, but we just felt that it wasn’t 
- well like the doctor said, it is treatable and so we continued. And not 
knowing the history of the 6 women who got heart failure or what 
happened to them. So it is hard for us to know what is the best thing to 
do. And I haven’t had a heart problem yet.” (p47)
In addition to trust in the system, some also believed that 
participation would provide access to what would become the new 
gold standard or the miracle drug. Such was the belief of the person 
who had severe diabetes and who had responded extremely well to the 
study drug; he was certain that study participants would be the first 
to receive prescriptions for the new drug. “I am waiting for the drug 
to be released. I will be the first patient in [my state] to sign up.”(p45) 
Another participant whose doctor had suggested participation added: 
“Well, then I started talking myself into it and he [the doctor] said 
the D-drug would be the new Lipitor, the miracle drug. That sounds 
so hopeful.” (p14) When holding such beliefs, research participants 
appeared to overlook the consequences of the research design such 
as randomization, the phase of the clinical trial, and other important 
factors. This was exemplified by the respondent who explained: “So I 
thought well if it works, I would be right in line and first to get the 
full treatment.” (p48) Participants also perceived that the additional 
time and more interaction with healthcare would translate into better 
treatment and personal benefit such as a cure for their disease. “Well 
at that time I did, though, at that time I didn’t see either benefits or 
risks. This is how naive I was. I thought maybe if it wasn’t a placebo 
maybe it would cure my osteoporosis.” (p16) Participation in a clinical 
study does indeed provide the opportunity to get more attention from 
a healthcare provider and often entails more tests than what is usually 
required. In the case of cancer trials, participation was often perceived 
as a last resort and the only way to gain access to treatment.
Given the overall approach to risk appraisal, few participants had 
any understanding, or even awareness, of the risks and challenges of 
data sharing or management. Persons who participated in genetic 
studies or longitudinal studies that required release of personal data, 
including DNA, also minimized risks associated with confidentiality 
and privacy reporting that they were not particularly concerned about 
any associated risk. When asked about the study’s provision of privacy 
protection said one participant: “I knew there couldn’t be much 
harm.” Another participant in a gene study noticed: “None really. I 
always worry about privacy issues but they said it was all identified by 
numbers and privacy would be safe.” Regardless of the type of study, 
the vast majority of participants (81%) presumed that the protection of 
privacy was adequate assuming that activities in a “legitimate” setting 
such as a hospital setting or researcher’s office setting would ensure 
such protection. Neither the understanding of what privacy protection 
should include nor who would have access to any data were well 
developed. Said one participant: “It was private. I was the only one. I 
was the only one in the room.” (p7) Others explained when asked about 
protection of privacy: “Didn’t even consider that.”(p1) “Yes. They seem 
to be careful of how they are handling phone calls and the personal 
upfront interview.” (p17) 
What participants need and want to know – The semi-structured 
instrument included questions about what the participants perceived 
as important information for decision-making regarding participation 
in research. Included in the instrument were questions such as: what 
are the most important pieces of information, what do you want 
to know; what do most people want to know, and were there any 
surprises? Generally the respondents wanted understandable and 
relevant information regarding what was required of them and what 
the “pros and cons” of participating would entail. Said one participant: 
“I think the risks and the time involvement. And the benefits. What 
do I get? What is the benefit to me personally? What am I going to get 
out of this? The results may not help me but maybe I get physicals and 
transportation and honorarium.” (p.5)The vast majority also wanted 
to make sure that they would not be harmed if they participated in 
the research. As one participant explained: “I think they want to make 
sure they are going to be safe and it won’t hurt them. They want to 
know there is some benefit for them. Some do it for totally altruistic 
reasons but most people want to see some benefit to them. Like trying a 
new medicine they wouldn’t be able to get otherwise. Like, I never had 
anything to treat this condition before and maybe I will get better if I 
am on the study. Most people hope they will get better; they hope they 
won’t get the placebo.” (p12) Those who participated in clinical trials 
wanted to make sure that they would get, at minimum, the standard of 
care. Participation then seemed to provide the added benefit of possible 
improvements on the current standard of care.
The findings suggest that regardless of background, education 
level, or age, participants consistently blurred the distinction between 
research and treatment. While affirming the importance of learning 
about risks, the participants also believed that they would not be invited 
to participate if the risks were other than minimal. Most believed that 
research would provide individual benefit and even optimal personal 
benefit. Two quotes reflect this orientation; “But I think there is an 
assumption that you make in a way - that if someone asks you to do 
this, like if a medical persons asks you - you think they already know 
the risks are minimal and they would not put you at a great deal of 
risk. They have your wellbeing at heart. That is how most people would 
think. But it may not be true. They are doctors. There is the trust thing.” 
(p21) “I think one wants to understand what the study is about. To 
make sure that information is straightforward. There was nothing 
about it being double blind, or placebo, or any negative consequences 
with being part of either group. I would not have participated if it had 
been random assignment to a group with shot and/or placebo.” (p18)
Most participants desired more information about two issues 
that generally are not fully explained or disclosed during the consent 
process: (1) the commercial purposes of the research and (2) the extent 
of researcher or institutional compensation. Regulatory guidelines do 
not currently stipulate how much information about either issue needs 
to be disclosed during the consent process. Prior to taking part in the 
interviews, most participants had not realized that some studies might 
be designed for commercial purposes, such as extending a patent or 
developing a “me-too” drug, a drug that replicates an already existing 
drug. Most of the participants were also unaware of the potential for 
researcher compensation. Participants thought it was dishonest not to 
be transparent about researcher compensation and the full purpose of 
a study and said that hiding such information would not be acceptable. 
Most (90%) wanted to know whether a study had such a commercial 
purpose and the vast majority (80%) reported that disclosure of such 
information could influence their decisions about participating in 
research in the future. Said one participant: “They should know; the 
person should know the purpose of the study. You have Ambien 12 
(hours) and Ambien CR (time release) and so they got the patent 
extended with the CR. They are looking at whether a formula makes 
a difference - and I think the study participant should be told exactly 
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what is going on. It’s coercion otherwise. We are looking at the 
formulary tweak. You have to be honest. If your study is not valid or 
fair or if you can’t tell the truth, rethink the study. You have to know 
the real purpose.” (P25). Said another: “Patents. Sure. Absolutely, for 
sure. I absolutely want to know. And I have a pretty high awareness of 
that issue and some of the drugs I have to take are still under patent and 
the costs are dramatically different from the generic drugs that I take.” 
(P28) Among those who said it would not influence their decisions 
about participation, they still felt they should be informed about such 
issues. 
Similarly, most participants (84%) wanted to be fully informed 
about researcher compensation. The tacit assumption among 
participants seemed to indicate a belief that the conduct of and 
participation in research studies included some level of altruism or 
mutuality on the part of both the researcher and the participant. One 
participant deliberated in this way on that topic: “I would think twice 
about a study if there was an enrollment or other [financial] incentive 
for the researcher. It would depend on the amount and if they could 
use tissue, blood or psychological profile for long term benefit. I would 
feel deceived if someone was getting an enrollment or other incentive 
and not tell me. It would make a difference who was funding the study. 
More information should be provided - a statement like compensation 
for research - it is misleading because you think it [what the researcher 
is getting] is on par with what is happening to you.”(p8) Another one 
said: “Yeah. That is pretty important information. Probably. Especially 
if there was a lot of compensation you might think twice about wanting 
to join. You would want to know if the doctor is doing it for the money. 
I would want to know if he is getting five grand for putting me through 
some study.”(p2) The importance of transparency was expressed by 
this participant: “I may be less inclined if I thought there was a possible 
COI - that whoever was funding it stands to benefit from the findings. 
If Pfizer was doing a study to show that their drug is the hottest thing 
on the market. I don’t have time for that kind of study. I would not 
participate; I would have no time for that. I can understand the benefit 
of running trials and trying to involve patients. I would want to know if 
my primary physician asked me, I would try to find out: OK could there 
be a benefit to my care provider by making me participate or framing 
data. And so if I started to feel pressure like someone really encouraging 
me, I would say no. I would immediately go into the terrible-two mode. 
If you are trying to push me…no thank you, I don’t want it. I have no 
time to sort through the potential conflicts.” (p5) “Wow. We didn’t 
know that - they get paid for helping to run these studies? Really? Yes. 
I would want to know. I didn’t realize they might get paid. Like my 
cancer nurse, is she paid by the cancer research foundation or how? 
Yes. I think you should know that. They should tell you. Who is getting 
paid and who is running the study and the whole reason why they are 
doing it. It is a matter of respect.” (p47) 
Willingness to join future research – When asked if they would 
be willing to participate in future studies 89% said they would join 
another study. Of those, 61% said they would join only under certain 
conditions. The “yes-but” group offered statements like: “I feel there are 
caveats.” (P14); “I would if I could get all of the information beforehand. 
Then I could make an informed decision. I could be thinking it over. 
I never even realized that doctors do research in their clinics.” (P7); 
“Well, it would depend on what the benefit would be and how much 
information I would be given. I am not adverse but I would now ask 
more questions.“ (P10); and “Yes but with a great deal more curiosity 
about the sponsors and the purpose of the study.“ (P19) There were also 
a few participants who expressed the view that if they had been put in 
the placebo or comparison group they would have withdrawn from the 
study. Said one mother whose child was participating in a behavioral 
study: “[We] will continue only if we are randomized to the telephone-
contact therapy (with me, as opposed to face-to-face meetings with [my 
child]. The study is a comparison between these two modalities.” (p15) 
Although most participants seemed relatively satisfied with their 
experiences of participating in research there were some for whom 
the experience was less than expected. Indeed all of those who said 
they would not participate in another study also reported negative 
experiences with their research participation. It appears that if a person 
had a less than optimal experience when participating in the research, 
it led to an expression of what could have been done better and what 
additional information could have been provided. Indicative of this 
perspective, one participant said: “I would like to know the results of 
other trials; is it totally new or are there some results? And I would like 
to know the difference between this stent and others. And I would like 
to know the benefits - what are you [the participant] going to get out 
of this…[is it] attention and follow-up? I think that is all part of the 
disclosure.” (p10) Another commented: “I mean thinking about this 
experience - I would have liked to have a better understanding of how I 
was going to feel. So even though it didn’t have permanent effects that 
I know of - other than bad memory - I would have liked to know what 
it was going to be like. I don’t recall having that described. Not to the 
degree of what I would experience.” (p4)
Almost all of the participants expressed a desire to receive study 
results. Many expressed that some form of closure would have been 
appropriate. When asked if there were surprises, many did say that they 
were disappointed that they had not been re-contacted and informed 
about study results as was promised or anticipated when enrolling. The 
participants reported that the lack of such information dampened their 
willingness to participate in future studies. 
Discussion
The findings from this study suggest that the guides that regulate 
the informed consent process – particularly the informed consent 
forms - may not be well aligned with the ways in which human subjects 
make decisions about participating in research. While claiming to have 
read the consent forms, most participants in this study had disregarded 
or discounted much of the information contained in them.  The 
required information about sponsorship/funder, full purpose of the 
study, risks, benefits, confidentiality and privacy was marginally 
registered if the research seemed “legitimate.” Key information in the 
consent forms was also disregarded or underestimated when the reason 
for participation was motivated by disease or some other personally 
compelling issue such as monetary reimbursement, an opportunity for 
the newest treatment or a “good deal” such as getting a flu shot for free. 
The participants seemed to make their decisions about participation 
based on intervening factors related to where the research is conducted 
(legitimacy of the setting), who conducts it (skilled clinician or 
colleague), and the relationship with or perceptions of the researcher 
(high levels of trust). When the research is offered in a clinic or other 
medical setting, participants appear to presume that the doctors or 
investigators know a great deal about the research and have considered 
all of the risks so that the participants will not be harmed. Thus even 
well-educated participants who stated that they read the informed 
consent documents for clinical studies seemed to make decisions based 
on their expectation of obtaining optimal treatment, the miracle drug, 
or the new gold standard. Participants did not fully understand that the 
study drugs may never make to it to the market, may be prohibitively 
expensive and so inaccessible to most people, or may have very serious 
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side effects or consequences. When enrolling in non-clinical studies 
participants often reported an obligation to participate so as not to 
disappoint, or jeopardize the relationship with the researcher. 
Indeed, there was such trust in the system and in the safety of 
participation that subjects often perceived that there was a greater 
personal risk associated with receiving either a placebo or the currently 
approved standard of care. If suspecting that they would be put in the 
placebo arm or existing treatment arm, some participants noted that 
they might even pull out of a study, a decision that could jeopardize 
randomization and so undermine the research integrity. Even those 
familiar with other types of research did not seem to transfer that 
knowledge when entering the medical realm via a clinical trial. What is 
surprising and deserving of attention when designing future policies for 
human subjects protection is that these findings consistently emerged 
even though this study was conducted with well educated, older people 
who would not have been deemed “vulnerable” or “at risk” in terms 
of their ability to read consent forms, understand the study, or make 
informed decisions. 
These findings suggest that current approaches for protecting 
human subjects, some of which include requiring that consent forms 
contain more information and more detail, are written at ever lower 
reading levels, or use checklists or videos to ascertain informed 
consent may fail to overcome the beliefs and expectations that the 
participants bring to the research enterprise. In part, participants may 
be conditioned by western society to expect and ignore all sorts of 
cautionary language. There are warnings if you get on a rollercoaster, 
visit a ski hill, or walk along a nature path. Televised pharmaceutical 
advertisements extol the benefits of the newest drug and then follow 
the claim with a long list of potential side effects. When arriving for 
a medical appointment, patients are quickly given HIPAA and other 
privacy-related forms; in response, with a quick glance, patients often 
ask where they are supposed to sign. This disregard of warnings seems 
to be carried over to the consent process where the desire to participate 
seems to override serious appreciation of risk. 
This kind of human behavior can also be understood by the 
theory of cognitive dissonance that suggests that individuals tend 
to seek consistency among their cognitions (i.e., beliefs, opinions) 
[36]. When there is an inconsistency between attitudes or behaviors 
(dissonance), something must change to eliminate the dissonance. In 
the case of a discrepancy between attitudes and behavior, it is most 
likely that the attitude will change to accommodate the behavior. There 
are three ways to eliminate dissonance: (1) reduce the importance of 
the dissonant beliefs, (2) add more consonant beliefs that outweigh 
the dissonant beliefs, or (3) change the dissonant beliefs so that they 
are no longer inconsistent [37]. Dissonance occurs most often in 
situations where an individual must choose between two incompatible 
beliefs: believing on one hand that research participation may have 
risks versus believing on the other hand that your clinician would 
not have suggested participation if the activity was risky. So in some 
respects, the extent to which the participants discounted information 
in the consent form, or even the process itself, is not surprising. Thus 
it is not more information in simplified language that matters when 
inviting participants to join a research study, but conveying the right 
information in ways that helps participants better understand how 
the goal of research and the goal of clinical care may be different from 
one another. Only when participants started thinking about issues 
like researcher/institutional compensation and commercial purposes 
of research such as obtaining patents or obtaining market shares did 
they begin to discern that there might be a difference between the goal 
of a particular research study and the goal of optimal individual care. 
Such recognition seemed to lead to a sort of “aaaha moment” whereby 
the participants then seemed to view issues such as receiving optimal 
personal care or not disappointing their doctor in a different light. 
These findings suggest that if we truly want to enroll enlightened 
volunteers, we have to find ways to communicate in practical terms 
the actual purpose of the study, the results of past studies, what the 
investigator knows about the research intervention, and what the 
investigator is being paid for helping carry out the research. Any 
strategies that would help the participants clarify the differences 
between the goals of research and the goals of personal care deserve 
further exploration. Our study did not explore how such information 
should be provided, or how it could influence enrollment. Thus more 
research is certainly warranted. We need to better understand the range 
of factors and beliefs that participants bring to their decision making. 
We also need to better understand how human subjects will experience 
greater transparency about the overall research process. 
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